drugset / Trial / NCT01919398
A Study of LY2940680 in Japanese Participants With Advanced Cancers
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to assess the safety and tolerability of LY2940680 up to the global recommended dose in Japanese participants with advanced solid cancers.
Timeline
- Start
- 2013-08
- Primary completion
- 2016-05
- Completion
- 2017-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Taladegib | Unknown | 100 mg | Oral |
| Subject | Taladegib | Unknown | 200 mg | Oral |
| Subject | Taladegib | Unknown | 400 mg | Oral |